Media stories about USANA Health Sciences (NYSE:USNA) have been trending somewhat positive this week, according to Accern Sentiment. Accern identifies positive and negative news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. USANA Health Sciences earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 46.120105018209 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
A number of research analysts recently issued reports on the company. TheStreet downgraded USANA Health Sciences from a “b+” rating to a “c+” rating in a report on Tuesday, February 6th. Pivotal Research lifted their price objective on USANA Health Sciences from $80.00 to $95.00 and gave the company a “buy” rating in a research report on Wednesday, February 7th. Finally, Sidoti cut USANA Health Sciences from a “buy” rating to a “neutral” rating in a research report on Wednesday, January 24th.
Shares of USANA Health Sciences (NYSE:USNA) opened at $81.90 on Tuesday. The firm has a market capitalization of $1,980.47, a P/E ratio of 32.50 and a beta of 0.94. USANA Health Sciences has a 12-month low of $52.55 and a 12-month high of $83.05.
USANA Health Sciences (NYSE:USNA) last posted its quarterly earnings data on Tuesday, February 6th. The company reported $1.11 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.00 by $0.11. The business had revenue of $273.11 million for the quarter, compared to analysts’ expectations of $258.67 million. USANA Health Sciences had a return on equity of 27.08% and a net margin of 5.97%. The business’s revenue was up 8.0% on a year-over-year basis. During the same period in the previous year, the firm posted $0.87 EPS. equities analysts predict that USANA Health Sciences will post 4.25 EPS for the current year.
In other news, CFO G Doug Iiekking sold 2,423 shares of the business’s stock in a transaction that occurred on Wednesday, March 7th. The stock was sold at an average price of $81.05, for a total value of $196,384.15. Following the sale, the chief financial officer now directly owns 2,423 shares of the company’s stock, valued at approximately $196,384.15. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Myron W. Wentz sold 228,000 shares of the business’s stock in a transaction that occurred on Monday, March 12th. The stock was sold at an average price of $81.10, for a total value of $18,490,800.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 689,767 shares of company stock worth $54,575,633. Insiders own 53.20% of the company’s stock.
USANA Health Sciences Company Profile
USANA Health Sciences, Inc develops and manufactures science-based nutritional and personal care products. The Company operates as a direct selling company in two geographic regions: Americas and Europe, and Asia Pacific, which includes three sub-regions: Southeast Asia Pacific, Greater China and North Asia.
Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.